{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"EP_2625195_B1","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"032-457-270-134-414"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11807,"type":"PATENT","title":"The University of Dundee Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":2439,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8437,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: uni* dundee. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2316
Search Applicants and Owners separately: uni* dundee. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2316
(i) CUCAGAUAUUGAGGGCUCUdTdT;
(ii) AGAGCCCUCAAUAUCUGAGdTdT;
(iii) GGGACAAGUUCAGCCAGAAdTdT; and
(iv) UUCUGGCUGAACUUGUCCCdTdT.said antisense nucleic acids being effective in modulating c20orf20 expression."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The compound of claim 5 for the use of claim 5, wherein the antibody or antigen binding fragment thereof, is specific or selective for one or more epitopes contained within a C20orf20 peptide selected from the group consisting of:
(a) CNPSSPSAAKRRRT
(b) GEAEVGGGGAAGDKGC
(c) CGKASEKSSKDKEKNSSD"],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising a polynucleotide for use according to claims 1 and 2 and/or polypeptide for use according to claims 3 and 4 and/or a compound for use according to any one of claims 5-7 together or in association with, a pharmaceutically acceptable excipient, carrier or diluent."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["Use of oligonucleotide/polypeptide probes and/or primers capable of hybridising to all or part of SEQ ID NOS: 2 and/or 7 in the detection and/or diagnosis of cSCC."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["A method of diagnosing cSCC or a predisposition or susceptibility thereto, said method comprising the steps of:
(a) providing a sample from a subject; and
(b) identifying a level of expression or activity in the sample, of the chromosome 20 open reading frame 20 (c20orf20) gene or its protein product or a fragment thereof;wherein the detection of aberrant levels of expression/activity of the c20orf20 gene its protein product or a fragment thereof, indicates that the subject is suffering from and/or susceptible/predisposed to cSCC."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein an oligonucleotide/polypeptide probe or primer capable of hybridising to all or part of SEQ ID NOS: 2 and/or 7 is used to identify a level of expression or activity of the genes and/or proteins in the sample."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["Use of a kit comprising a substrate having (i) the chromosome 20 open reading frame 20 (c20orf20) protein or a fragment thereof bound thereto; or (ii) an antibody capable of binding to a chromosome 20 open reading frame 20 (c20orf20) protein or fragment thereof bound thereto; and one or more components selected from the group consisting of:
(a) an antibody according to claim 7;
(b) one or more oligonucleotides/primers for detecting/amplifying/probing nucleic acid samples for aberrant or modulated c20orf20 expression, function and/or activity; and
(c) instructions for use;in the diagnosis, detection or evaluation cSCC in a subject."],"number":12,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}